2. Search Result
Search Result
Pathways Recommended: Membrane Transporter/Ion Channel
Results for "

Membrane disruption

" in MedChemExpress (MCE) Product Catalog:

61

Inhibitors & Agonists

1

Screening Libraries

4

Biochemical Assay Reagents

12

Peptides

1

MCE Kits

3

Natural
Products

3

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Area
  • HY-P5753A
    JB-95 acetate

    		Bacterial Infection
    JB-95 acetate, a β-hairpin macrocyclic peptide, exhibits potent antimicrobial activity against Escherichia coli. JB-95 acetate can selectively disrupt the outer membrane but not the inner membrane of E. coli .
  • HY-126810A
    NP213 TFA

    		Fungal Infection
    NP213 TFA is a rapidly acting, novel, first-in-class synthetic antimicrobial peptide (AMP), has anti-fungal activities. NP213 TFA targets the fungal cytoplasmic membrane and plays it role via membrane perturbation and disruption. NP213 TFA is effective and well-tolerated in resolving nail fungal infections .
  • HY-P5345
    KLA peptide

    		Peptides Others
    KLA peptide is a biological active peptide. (a cationic amphipathic mitochondrial membrane disrupting peptide that induces programmed cell death by disrupting mitochondrial membrane, but cannot cross the plasma membrane)
  • HY-P5286
    BMAP-27

    		Bacterial Infection Cancer
    BMAP-27 is an antimicrobial peptide capable of disrupting the membrane integrity of microorganisms. Due to its membrane permeability, MAP-27 has inhibitory activity against both bacteria and cancer cells .
  • HY-P5753
    JB-95

    		Bacterial Infection
    JB-95, a β-hairpin macrocyclic peptide, exhibits potent antimicrobial activity against Escherichia coli. JB-95 can selectively disrupt the outer membrane but not the inner membrane of E. coli .
  • HY-P3707
    Tumor targeted pro-apoptotic peptide

    		Apoptosis Cancer
    Tumor targeted pro-apoptotic peptide (CNGRC-GG-D(KLAKLAK)2) is an anti-tumor peptide. Tumor targeted pro-apoptotic peptide disrupts mitochondrial membranes and promotes apoptosis, showing anticancer activity in mice .
  • HY-P4121
    L17E

    		Peptides Metabolic Disease
    L17E, an endosomolytic peptide, is a cationic amphiphilic peptide with specific membrane lytic activity for late endosomes (LEs). L17E diminishes the TS5-p45 induced apoptosis in a dose-dependent manner. L17E is endocytosed into cells and trafficked to LEs. Within the acidic environment of LEs, L17E perturbs and lyses the LE membrane, leading to disruption of LE membrane and release of LE content to the cytosol. L17E is used to investigate the role of the endosomal protein trafficking pathway .
  • HY-P3350
    LS-BF1

    		Bacterial Infection
    LS-BF1 is a stable and low toxic cationic antimicrobial peptide. LS-BF1 displays broad spectrum of antibacterial activity, including the challenging ESKAPE pathogens, by cell membrane disruptive mechanism. LS-BF1 shows good in vivo efficacy for elimination of bacteria in a mouse infection model[1].
  • HY-P5601
    Thanatin

    		Bacterial Fungal Infection
    Thanatin is an inducible cationic antimicrobial peptide. Thanatin is a pathogen-inducible single-disulfide-bond-containing β-hairpin AMP. Thanatin displays broad-spectrum activity against both Gram-negative and Gram-positive bacteria as well as against various species of fungi with MICs of 0.3-40 µM, 0.6-40 µM and 0.6-20 µM, respectively. Thanatin has the property of competitive replacement of divalent cations from bacterial outer membrane (OM), leading to OM disruption .
  • HY-P5601A
    Thanatin TFA

    		Bacterial Fungal Infection
    Thanatin TFA is an inducible cationic antimicrobial peptide. Thanatin TFA s a pathogen-inducible single-disulfide-bond-containing β-hairpin AMP. Thanatin TFA displays broad-spectrum activity against both Gram-negative and Gram-positive bacteria as well as against various species of fungi with MICs of 0.3-40 µM, 0.6-40 µM and 0.6-20 µM, respectively. Thanatin TFA has the property of competitive replacement of divalent cations from bacterial outer membrane (OM), leading to OM disruption .
  • HY-P2307A
    Tat-NR2Baa TFA

    		iGluR NO Synthase Neurological Disease
    Tat-NR2BAA TFA is the control peptide of Tat-NR2B9c (HY-P0117), inactive. The sequence of Tat-NR2BAA TFA is similar to Tat-NR2B9c, but it has a double-point mutation in the COOH terminal tSXV motif, making it incapable of binding PSD-95. Tat-NR2B9c is a membrane-permeant peptide and disrupts PSD-95/NMDAR binding, correlate with uncoupling NR2B- and/or NR2A-type NMDARs from PSD-95 .
  • HY-P2307
    Tat-NR2Baa

    		iGluR NO Synthase Neurological Disease
    Tat-NR2BAA is the control peptide of Tat-NR2B9c (HY-P0117), inactive. The sequence of Tat-NR2BAA is similar to Tat-NR2B9c, but it has a double-point mutation in the COOH terminal tSXV motif, making it incapable of binding PSD-95. Tat-NR2B9c is a membrane-permeant peptide and disrupts PSD-95/NMDAR binding, correlate with uncoupling NR2B- and/or NR2A-type NMDARs from PSD-95 .

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: